|1.||Cao, Ling-Yan: 1 article (12/2003)|
|2.||Huang, He: 1 article (12/2003)|
|3.||Ni, Jiang-Hong: 1 article (12/2003)|
|4.||LoRusso, P M: 1 article (08/2000)|
|5.||Purvis, J: 1 article (08/2000)|
|6.||Drozd, M: 1 article (08/2000)|
|7.||Ruble, P E: 1 article (08/2000)|
|8.||Lockwood, G F: 1 article (08/2000)|
|9.||Heilbrun, L K: 1 article (08/2000)|
|10.||Corbett, T H: 1 article (08/2000)|
|1.||Prostatic Neoplasms (Prostate Cancer)
08/01/2000 - "SR233377 is a novel thioxanthenone analogue that demonstrated solid tumor selectivity in vitro with activity confirmed in vivo against several murine tumors including those of colon, pancreas, and mammary origin. "
01/01/1999 - "We conclude that SR233377 administered on a 5-day schedule is associated with tolerable clinical symptoms and some activity against a range of solid tumors but dosing is limited by QTc prolongation, a condition that predisposes to ventricular arrhythmias. "
01/01/1999 - "A group of 25 patients with a range of solid tumor diagnoses and good performance status received SR233377 at eight dose levels ranging from 4.8 mg/m2 per day to 74.7 mg/m2 per day. "
01/01/1999 - "SR233377 (WIN33377) is a novel 4-aminomethyl thioxanthone derivative with promising preclinical activity against solid tumors at doses substantially below the MTD. "
|1.||Megestrol Acetate (Borea)
|2.||Medroxyprogesterone Acetate (Depo-Provera)